As of June 30, 2026, Immix Biopharma, Inc. carries a market capitalization of 737.53M, placing it among publicly traded companies globally. Its enterprise value stands at 506.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 737.53M |
| Enterprise Value | 506.43M |
Immix Biopharma, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of June 30, 2026, Immix Biopharma, Inc. has 71.54M shares outstanding.
| Shares Outstanding | 71.54M |
These figures are as of June 30, 2026.
| PB Ratio | 3.22 |
| P/TBV Ratio | 3.22 |
| P/FCF Ratio | -12.49 |
| P/OCF Ratio | -12.68 |
As of June 30, 2026, Immix Biopharma, Inc. maintains a current ratio of 25.13, meaning it holds 25.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 25.13 |
| Quick Ratio | 24.95 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | -0.02 |
Over the twelve months ended June 30, 2026, Immix Biopharma, Inc. posted a negative return on equity (ROE) of -34.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.34, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 21.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -34.18 |
| Return on Assets (ROA) | -31.34 |
| Employee Count | 21.00 |
Over the twelve months ended June 30, 2026, Immix Biopharma, Inc. recorded 33,310.00 in income tax expense. The company reported a pretax loss of -39.88M and -39.92M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 33,310.00 |
As of the close on November 16, 2026, Immix Biopharma, Inc.'s stock has gained approximately 77.67% over the past 52 weeks. The 50-day moving average sits at 9.69, while the 200-day moving average is 9.62.
| 52-Week Price Change | 77.67% |
| 50-Day Moving Average | 9.69 |
| 200-Day Moving Average | 9.62 |
Over the twelve months ended June 30, 2026, Immix Biopharma, Inc. generated - - in revenue and converted that into -39.92M in net income, yielding earnings per share of -0.84. EBITDA reached -41.33M, while operating income came in at -41.82M.
| Operating Income | -41.82M |
| Pretax Income | -39.88M |
| Net Income | -39.92M |
| EBITDA | -41.33M |
| EBIT | -41.82M |
| Earnings Per Share (EPS) | -0.84 |
As of June 30, 2026, Immix Biopharma, Inc. holds 232.11M in cash and equivalents against 1.00M in total debt, resulting in a net debt position of -225.49M. Total book value stands at 228.92M, with working capital of 224.49M providing operational flexibility.
| Cash & Cash Equivalents | 232.11M |
| Total Debt | 1.00M |
| Net Debt | -225.49M |
| Equity (Book Value) | 228.92M |
| Book Value Per Share | 3.20 |
| Working Capital | 224.49M |
Immix Biopharma, Inc. produced -38.50M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -591,111.00 in capital expenditures, free cash flow totaled -39.09M - equivalent to -0.83 per share.
| Operating Cash Flow | -38.50M |
| Capital Expenditures | -591,111.00 |
| Free Cash Flow | -39.09M |
| FCF Per Share | -0.83 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -35.46, meaning Immix Biopharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -35.46 |
| FCF Yield | -8.01 |
As of June 30, 2026, Immix Biopharma, Inc. has an Altman Z-Score of 43.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 43.23 |